Our STEM Live-cel therapy approach is an improvement over intermittent enzyme exposure with recombinant protein enzyme replacement therapy (ERT) . Unlike traditional ERT, our autologous-derived STEM Live-cel therapy provides uninterrupted cross-correction therapy - the patient obtains a more continuous supply of enzyme. The durability of our STEM Live-cell therapy is now demonstrated to exceed 5 years ((PMID 39794302). This indicates the hassle of every other week infusions can be avoided for many years. Furthermore, the transplanted leukocytes are known to spread systemically to a wide variety of compartments in the body, including the brain, thus the blood brain barrier problem with traditional recombinant protein transfusions is a much lower obstacle. As a result, successful treatment of neurological complications of enzyme deficiency can be expected.